From: Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study
r/n | OR (unadjusted), 95% CI | p | aOR (adjusted), 95% CI | p | |
---|---|---|---|---|---|
Treatment | |||||
HRZE | 10/138 | ||||
2MHRZ/2MHR | 11/149 | 0.98 (0.40–2.43) | 0.973 | – | – |
2EMRZ/2MR | 18/139 | 1.93 (0.84–4.39) | 0.119 | ||
Age | |||||
≤ 30 years | 20/223 | 1.0 | – | – | |
> 30 years | 19/203 | 0.95 (0.48–1.88) | 0.881 | ||
BMI | |||||
< 18.5 | 19/189 | 1.0 | – | – | |
≥ 18.5 | 20/237 | 1.03 (0.51–2.12) | 0.926 | ||
Race | |||||
Asian | 15/135 | 1.0 | |||
Black | 9/163 | 0.39 (0.14–1.08) | 0.070 | – | – |
Mixed race and Caucasian | 15/128 | 0.45 (0.14–1.45) | 0.182 | ||
Smoking | |||||
Never smoked | 21/292 | 1.0 | 1.0 | ||
Ever smoked | 18/134 | 2.69 (0.92–7.90) | 0.071 | 2.00 (1.03–3.90) | 0.041 |
HIV | |||||
Negative | 36/385 | 1.0 | – | – | |
Positive | 3/41 | 1.16 (0.28–4.84) | 0.835 | ||
Cavities | |||||
No cavities | 9/110 | 1.0 | – | – | |
Cavities | 30/316 | 1.16 (0.51–2.63) | 0.715 |